198 related articles for article (PubMed ID: 29383359)
21. L1198F Mutation Resensitizes Crizotinib to ALK by Altering the Conformation of Inhibitor and ATP Binding Sites.
Li J; Sun R; Wu Y; Song M; Li J; Yang Q; Chen X; Bao J; Zhao Q
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245558
[TBL] [Abstract][Full Text] [Related]
22. Binding and discerning interactions of PTP1B allosteric inhibitors: novel insights from molecular dynamics simulations.
Shinde RN; Sobhia ME
J Mol Graph Model; 2013 Sep; 45():98-110. PubMed ID: 24012873
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode.
Gummadi VR; Rajagopalan S; Looi CY; Paydar M; Renukappa GA; Ainan BR; Krishnamurthy NR; Panigrahi SK; Mahasweta K; Raghuramachandran S; Rajappa M; Ramanathan A; Lakshminarasimhan A; Ramachandra M; Wong PF; Mustafa MR; Nanduri S; Hosahalli S
Bioorg Med Chem Lett; 2013 Sep; 23(17):4911-8. PubMed ID: 23880539
[TBL] [Abstract][Full Text] [Related]
25. Drug Design for ALK-Positive NSCLC: an Integrated Pharmacophore-Based 3D QSAR and Virtual Screening Strategy.
James N; Shanthi V; Ramanathan K
Appl Biochem Biotechnol; 2018 May; 185(1):289-315. PubMed ID: 29134510
[TBL] [Abstract][Full Text] [Related]
26. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
Ai X; Shen S; Shen L; Lu S
Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
28. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
29. Insight into the structural mechanism for PKBα allosteric inhibition by molecular dynamics simulations and free energy calculations.
Chen SF; Cao Y; Han S; Chen JZ
J Mol Graph Model; 2014 Mar; 48():36-46. PubMed ID: 24374242
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R.
Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X
Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809
[TBL] [Abstract][Full Text] [Related]
31. Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques.
Wang JL; Cheng LP; Wang TC; Deng W; Wu FH
J Mol Graph Model; 2017 Mar; 72():178-186. PubMed ID: 28107751
[TBL] [Abstract][Full Text] [Related]
32. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
33. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Zhan JY; Zhang JL; Wang Y; Li Y; Zhang HX; Zheng QC
J Biomol Struct Dyn; 2016 Nov; 34(11):2351-66. PubMed ID: 26549408
[TBL] [Abstract][Full Text] [Related]
34. Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors.
Araujo SC; Maltarollo VG; Almeida MO; Ferreira LLG; Andricopulo AD; Honorio KM
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936488
[TBL] [Abstract][Full Text] [Related]
35. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
Roskoski R
Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
[TBL] [Abstract][Full Text] [Related]
36. Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
Almeida MO; Costa CHS; Gomes GC; Lameira J; Alves CN; Honorio KM
J Biomol Struct Dyn; 2018 Nov; 36(15):4010-4022. PubMed ID: 29132261
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances in the Discovery of CK2 Allosteric Inhibitors: From Traditional Screening to Structure-Based Design.
Chen X; Li C; Wang D; Chen Y; Zhang N
Molecules; 2020 Feb; 25(4):. PubMed ID: 32079098
[TBL] [Abstract][Full Text] [Related]
38. Importance of protein flexibility in ranking ERK2 Type I
Niu Y; Yao X; Ji H
RSC Adv; 2019 Apr; 9(22):12441-12454. PubMed ID: 35515820
[TBL] [Abstract][Full Text] [Related]
39. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
40. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Davare MA; Vellore NA; Wagner JP; Eide CA; Goodman JR; Drilon A; Deininger MW; O'Hare T; Druker BJ
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):E5381-90. PubMed ID: 26372962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
